RenovoRx, Inc., a life sciences company pioneering targeted oncology treatments, has announced its participation in the upcoming Alliance Global Partners (A.G.P.) Virtual Healthcare Company Showcase on May 21, 2025. During the event, CEO Shaun Bagai will join a fireside chat moderated by Scott Henry, Managing Director and Healthcare Analyst at A.G.P. The conversation will focus on the company's recent business developments, including the ongoing commercialization of RenovoCath®, a novel, FDA-cleared drug-delivery device, and clinical advancements in its Phase III TIGeR-PaC trial.

The innovation at the heart of RenovoRx’s approach lies in RenovoCath®, which delivers chemotherapy (intra-arterial gemcitabine) directly to tumors with high precision. This method aims to maximize drug concentration at the tumor site while minimizing systemic exposure and side effects—a critical advancement for treating hard-to-reach cancers like locally advanced pancreatic cancer (LAPC). The ongoing TIGeR-PaC trial evaluates this drug-device combination's safety and efficacy, offering potential for improved outcomes in a disease with historically limited treatment success.

This update underscores RenovoRx's growing impact in oncology, particularly in targeting complex, late-stage cancers. By participating in high-profile industry events like the A.G.P. showcase, the company reinforces its leadership and momentum in commercializing precision-based therapies. If successful, its technology could set a new standard in how solid tumors are treated, representing a significant leap forward in personalized cancer care.

MedTech Spectrum's Summary

Innovation: RenovoRx’s RenovoCath® system represents a novel drug-device combination that delivers chemotherapy (intra-arterial gemcitabine) directly to tumors, enhancing local efficacy while minimizing systemic toxicity—a significant advancement in targeted cancer therapy.

Usage: Currently under investigation in the Phase III TIGeR-PaC trial, this technology is being tested for the treatment of locally advanced pancreatic cancer (LAPC), aiming to offer a more effective and safer alternative to conventional systemic chemotherapy.

Importance: By showcasing its clinical progress and commercialization efforts at the A.G.P. Virtual Healthcare Company Showcase, RenovoRx is highlighting its potential to transform the standard of care in oncology and improve patient outcomes in one of the most challenging cancer types.